HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $23
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Caribou Biosciences (NASDAQ:CRBU) but lowers the price target from $25 to $23.
July 26, 2023 | 10:23 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Caribou Biosciences' price target has been lowered from $25 to $23 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The news directly pertains to Caribou Biosciences as the company's price target has been lowered by HC Wainwright & Co. However, the 'Buy' rating is maintained which indicates a positive outlook for the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100